CN106987560A - The construction method of the stable strain of the cell HB gene knockouts of RK 13 - Google Patents
The construction method of the stable strain of the cell HB gene knockouts of RK 13 Download PDFInfo
- Publication number
- CN106987560A CN106987560A CN201710200878.3A CN201710200878A CN106987560A CN 106987560 A CN106987560 A CN 106987560A CN 201710200878 A CN201710200878 A CN 201710200878A CN 106987560 A CN106987560 A CN 106987560A
- Authority
- CN
- China
- Prior art keywords
- sgrna
- gene
- cell
- cells
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of construction method of the stable strain of cell HB gene knockouts of RK 13;Methods described comprises the following steps:The sgRNA of a pair of complementary targeting rabbit HB second extrons of gene of design, using pSpCas9 (BB) 2A Puro (PX459) V2.0 plasmids as carrier, builds eukaryotic expression recombinant plasmid;After sequencing identification, eukaryotic expression recombinant plasmid cotransfection is entered in the cells of RK 13, positive cell screening is carried out using puromycin, separation monoclonal cell is cultivated;Effect is knocked out with sequencing identification.The plasmid that the present invention is built carries the Cas9 endonuclease genes of micrococcus scarlatinae II type CRISPR/Cas9 systems;CRISPR/Cas9 gene editings technology success permanent knockout RK 13 cell HB genes, obtain HB and knock out stable cell line, are taken a firm foundation for the function of studying HB genes.
Description
Technical field
The invention belongs to gene engineering technology field, and in particular to a kind of structure of the stable strain of RK-13 cells HB gene knockouts
Construction method.
Background technology
CRISPR (clustered, regularly interspaced, short palindromic repeats) is one
Plant the viral DNA invaded from bacterial degradation or the immunologic mechanism of other exogenous DNAs.Cas9 albumen first with crRNA and
TracrRNA is combined into compound, then by recognizing PAM sequences (5 '-NGG-3 ') combination and invading DNA, then cutting DNA
Double-strand, causes missing or the insertion of base, causes gene silencing.Scientist carries out gene using CRISPR/Cas9 systems
The work of editor, is the gene orientation editing technique of a new generation.Sweden female microbiologist Emmanuelle in 2011
Charpenti exists《Nature》On publish thesis, illustrate the mechanism of action of the immune system Cas9 in bacterial body, pass through this set
RNA mediated dnas cutting mechanism makes bacterium from the invasion of exogenous DNA and proposes 4 key factors Cas9, crRNA,
TracrRNA, and RNaseIII.The scientist Jennifer Doudna of subsequent Univ California-Berkeley in 2012
《Science》On publish thesis, realize the external editor of genome first using this immune system, indicate CRISPR
Formal birth.The scientist Zhang Feng Polymorphisms group expert George Church of Chinese origin of Blanc moral research institute in 2013 are common
《Science》On delivered landmark CRISPR achievements in research, determining for gene is realized on mammalian cell first
Point editor, indicates that this technology has moved to maturity, to realize that the point of application of technology has determined important foundation.The current technology is
Only need to express Cas9 endonucleases and corresponding sgRNA molecules in the cell through developing into, almost can be to arbitrary DNA
Sequence is cut.The key point of this technology is exactly to design sgRNA molecules, and is linked in carrier, easy to operate.
Compared to preceding two generations gene targeting:Zinc finger endonuclease (zinc finger endonuclease, ZFN)
With class activating transcription factor effector nuclease (transcription activator-like effector nuclease,
The classical gene targeting such as TALEN), CRISPR/Cas9 gene editing system addresses with low cost, easy to operate, system
The standby cycle is short, the advantages of efficiency high, and the rapid worldwide laboratories of CRISPR/Cas9, this technology makes gene editing technology
It can be carried out in common Molecular Laboratory.Within short 1 year, bio-science field is had become most very powerful and exceedingly arrogant
Research tool.
Current CRISPR/Cas9 technologies are successfully applied to the genome essence of human cell, zebra fish and mouse and bacterium
True modification, modified types include gene site-directed InDe1 be mutated, it is gene site-directed knock in, two site simultaneous mutations and small fragment lack
Lose.Because its mutation efficiency is high, make the characteristics of simple and cost is low, it is considered to be a kind of gene with broad prospect of application
Group fixed point transformation molecular tool.
Hemoglobin β-chain thought the protein simply with oxygen carrying capacity in the past always, during bacterium infection
Blood transportation can be accelerated, and then promote the removing to bacterium.There is document report classical swine fever virus C protein can be with HB
Interact and propagation of the CSFV on cell can be suppressed, interference HB expression virus titers rise, and we can profit
Downstream experiment is carried out with the cell line of knockout,.Rabbit hemorrhagic disease virus belongs to Caliciviridae Lagovirus, very long one section in the past
Time is because without suitable cell culture system, cause the viral research relatively backward with respect to other positive chain RNA virus, nothing
Method carries out appropriate cell experiment, the nucleotide sequence that our laboratories pass through the capsid protein surface amino groups acid molecule to RHDV
Rite-directed mutagenesis is carried out, improved virus can be bred on RK-13 cells, achieve breakthrough development, this causes us
RHDV can be allowed to rise in value on cell and carry out downstream experiment.
The content of the invention
It is an object of the invention to provide a kind of construction method of the stable strain of RK-13 cells HB gene knockouts;It is specifically sharp
HB genes in RK-13 cells are knocked out with the CRISPR/Cas9 gene editings system of improvement, RK-13 cell HB gene knockouts are built
Stable strain.
The purpose of the present invention is achieved through the following technical solutions:
The present invention relates to a kind of construction method of the stable strain of RK-13 cells HB gene knockouts, methods described includes following step
Suddenly:
S1, a pair of complementary targeting rabbit HB second extrons of gene of design sgRNA, with pSpCas9 (BB) -2A-
Puro (PX459) V2.0 plasmids are carrier, construct an eukaryotic expression recombinant plasmid;
S2, after sequencing identification, the eukaryotic expression recombinant plasmid is transfected into RK-13 cells, using fast jointly
Purine mycin carries out positive cell screening, and separation monoclonal cell is cultivated;Effect is knocked out with sequencing identification, you can obtain RK-
The stable strain of 13 cell HB gene knockouts.
As a result:Sg RNA are properly inserted into PX459 plasmid vectors, are transfected and are screened WB in the cell after monoclonal and verify
HB protein expressions are lacked.
Conclusion:Successfully construct the stable strain of RK-13 cell HB gene knockouts.
It is preferred that, in step S1, the sequence of the sgRNA includes the forward primer HB- as shown in SEQ ID NO.1
SgRNAF sequences, and the reverse primer HB-sgRNAR sequences as shown in SEQ ID NO.2.
It is preferred that, in step S1, the structure specifically includes following steps:
S1-1, using Bbs I restriction enzymes pSpCas9 (BB) -2A-Puro (PX459) V2.0 plasmids are entered into line
Property, and be incubated using alkaline phosphatase, remove plasmid end sequence phosphorylation after digestion;Then agarose gel electrophoresis is pure
Change, reclaim DNA fragmentation;
S1-2, the single-stranded annealing of two sgRNA oligonucleotides formed into double-strand, and through T4 tyrosine phosphorylations;Annealing
Product and the DNA fragmentation of the recovery are attached using T4 DNA ligases, and are converted into Stb13 competent cells, are chosen
Take monoclonal bacterium colony;
S1-3, it is sequenced as primer with U6 promoters, extracts sequencing correct plasmid.
It is preferred that, in step S1-2, the program of T4 tyrosine phosphorylations is 37 DEG C of 30min, 95 DEG C of 5min, and 90 DEG C to 25 DEG C are every
Minute declines 5 DEG C, 4 DEG C of preservations.
The invention further relates to a kind of eukaryotic expression recombinant plasmid of targeting knock out RK-13 cells HB genes, the restructuring is true
Nuclear expression plasmid is the sgRNA by designing a pair of complementary targeting rabbit HB second extrons of gene, with pSpCas9
(BB) -2A-Puro (PX459) V2.0 plasmids are eukaryotic expression recombinant plasmid obtained by vector construction.
It is preferred that, the sequence of the sgRNA includes the forward primer HB-sgRNAF sequences as shown in SEQ ID NO.1, and
Reverse primer HB-sgRNAR sequences as shown in SEQ ID NO.2.
The present invention has the advantages that:
The present invention is carried suppurative using pSpCas9 (BB) -2A-Puro (PX459) V2.0 (PX459-HB) built
The Cas9 endonuclease genes of streptococcus II type CRISPR/Cas9 systems;The success of CRISPR/Cas9 gene editings technology is permanent
Property knocked out RK-13 cell HB genes, obtain HB knock out stable cell line, be in the future research HB genes function lay heavily fortified point
Real basis.
Brief description of the drawings
By reading the detailed description made with reference to the following drawings to non-limiting example, further feature of the invention,
Objects and advantages will become more apparent upon:
Fig. 1 is two sgRNA design synthesis principle schematic diagrames;
Fig. 2 is RK-13 cells and knocks out strain HB gene order-checking result AB1 files comparison schematic diagram;Wherein, upper figure is
RK-13 cellular genome sequencing result AB1 files, figure below is knockout strain HB gene order-checking result AB1 files;
Fig. 3 is RK-13 cells and knocks out strain HB gene order-checking result SEQ files comparison schematic diagram;Wherein, upper figure is
RK-13 cellular genome sequencing result SEQ files, figure below is knockout strain HB gene order-checking result SEQ files;
Fig. 4 is WB detection RK-13 cells and knocks out strain HB gene knockouts effect and β-actin controls;Wherein, left figure is
RK-13 knocks out cell line effect, and right figure compares for β-actin.
Embodiment
With reference to embodiment, the present invention is described in detail.Following examples will be helpful to those skilled in the art
The present invention is further understood, but the invention is not limited in any way.It should be pointed out that to one of ordinary skill in the art
For, without departing from the inventive concept of the premise, it can also make certain adjustments and improvements.These belong to the guarantor of the present invention
Protect scope.
Embodiment
1:Materials and methods
1.1 experiment material:1.1.1 plasmid, bacterial strain and cell CRISPR/Cas9n plasmids pSpCas9 (BB) -2A-Puro
(PX459) V2.0 is preserved purchased from addgene and by laboratory, and RK-13 cells are purchased from Wuhan University's cyropreservation center.Competence
Cell Stb13 is purchased from Beijing Quan Shi King Companies.Plasmid map is found in http://www.addgene.org websites.
1.1.2 main agents:Bbs I restriction enzymes, T4 ligase, 10xT4Ligation Buffer,
10mmol/L ATP are purchased from NEB companies;AxyPrep DNA gels QIAquick Gel Extraction Kit is limited purchased from love biotechnology (Hangzhou) of pursuing progress
Company;The a large amount of extracts kits of plasmid are purchased from QIAGEN companies;Lipo2000 transfection reagents are purchased from Invitrogen companies;
Opti-MEM culture mediums are purchased from Gbico companies;MEM culture mediums are purchased from Hyclone companies, and mouse source HB polyclonal antibodies are by this experiment
Room prepares and preserved, and mouse source β-actin antibody, the anti-mouse IgG of horseradish peroxidase mark are century purchased from health.Gene sequencing and
SgRNA synthesis is completed by Shanghai Hua Jin bio tech ltd.
1.2 method:
1.2.1 the design of sgRNA oligo sequences
The design application http of sgRNA oligo sequences:1 pair of //crispr.mit.edu/ website designs are directed to HB cds
The sgRNA sequences of the extron in area.Design method is following (principle such as Fig. 1):(1) the HB genome cds areas issued according to NCBI
Sequence, the sequence that about 200bp is rich in NGG is found behind initiation codon, the website is committed to, and sgRNA sequences can only be
On same extron, it is impossible to across two extrons because extron in genome across intron sequences.(2) basis
The result that website is provided, higher several to sequence of selection fraction, restriction enzyme site is added at its two ends.In every sgRNA sequence F chain
5 ' end addition CACC, 5 ' end addition AAAC of R chains, the cohesive terminus,cohesive termini formed with pX4592.0 plasmids after Bbs I digestions is mutual
Mend.5 ' first base in end such as F chains are not G, then add a G behind 5 ' end CACC, and correspondingly 3 ' ends of R chains are further added by
One C.2 pX4592.0 recombinant plasmids are referred to as pX459- Δs HB below.
The sgRNA oligonucleotide sequences of table 1
Title | Sequence (5-3) |
HB-sgRNA F | CACCGCAAAGGACTCGAAGAACCTC(SEQ ID NO.1) |
HB-sgRNA R | AAACGAGGTTCTTCGAGTCCTTTGC(SEQ ID NO.2) |
1.2.2 the structure of recombinant plasmid
Enzyme pSpCas9 (BB) -2A-Puro (PX459) V2.0 plasmids are carried out using Bbs I restriction enzymes linear
Change, and 30min is incubated at 37 DEG C using alkaline phosphatase (CIP), remove plasmid end sequence phosphorylation after digestion;Then 1%
Agarose gel electrophoresis is purified, and wall scroll DNA fragmentation is remained as after pSpCas9 (BB) -2A-Puro (PX459) V2.0 plasmid enzyme restrictions,
DNA fragmentation is reclaimed with glue reclaim kit, and linearisation 50ng/ul is diluted to, moved back two sgRNA oligonucleotides are single-stranded
Fire forms double-strand, and through T4 tyrosine phosphorylations, and program is 37 DEG C of 30min, 95 DEG C of 5min, and 90 DEG C to 25 DEG C per minute to decline 5 DEG C,
4 DEG C of preservations;Annealed product is diluted with ultra-pure water 1: 200, is then attached using T4 DNA ligases, and is converted extremely
In Stb13 competent cells, picking monoclonal bacterium colony is sequenced with U6 promoters as primer.Will sequencing correct plasmid profit
Extraction reagent kit in endotoxin is gone to extract plasmid with Qiagene.Positive cell is screened:Cell transfecting:RK-13 cells, which are used, contains 10% tire
The MEM cultures of cow's serum (FBS) are based on 5%CO2, and 37 DEG C incubated.24h before transfection, phase cell of taking the logarithm is with 5 × 105/ hole
6 orifice plate cultures are inoculated into, and are named, and set up negative control group.Step will knock out plasmid with lipo3000 and turn to specifications
Contaminate into RK-13 cells, changed after 6h after liquid, 48h plus puromycin screens vitellophag after positive cell, then 48h, and progressively added
Big puromycin concentration, will grow the cell dissociation after stabilization, collects cell and simultaneously counts, infinite dilution is micro- into 96 hollow plates
Microscopic observation individual cells are simultaneously marked, and carry out Colony Culture, when individual cells are agglomerating, then expand culture step by step, are collected
Part cell extraction genomic DNA, target gene after being expanded through PCR be connected and be sequenced with carrier T, is entered with wild type gene group
Row is compared, checking HB genes whether successful knockout.The cell expansion culture of base will be successfully lacked, extract total protein of cell, WB
Checking knocks out efficiency.
Gene order-checking result as shown in Figure 2,3, from Fig. 2,3, knocks out strain HB genes and 10 alkali is lacked at sgRNA
Base, causes frameshift mutation.
WB detects HB gene knockouts result as shown in figure 4, as shown in Figure 4, successful knockout HB genes.
The specific embodiment of the present invention is described above.It is to be appreciated that the invention is not limited in above-mentioned
Particular implementation, those skilled in the art can make various deformations or amendments within the scope of the claims, this not shadow
Ring the substantive content of the present invention.
SEQUENCE LISTING
<110>China Agriculture Academe Shanghai Veterinary Institute
<120>The construction method of the stable strain of RK-13 cell HB gene knockouts
<130> DAG28951
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Artificial Sequence
<400> 1
caccgcaaag gactcgaaga acctc 25
<210> 2
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Artificial Sequence
<400> 2
aaacgaggtt cttcgagtcc tttgc 25
Claims (6)
1. the construction method of the stable strain of a kind of RK-13 cells HB gene knockouts, it is characterised in that methods described includes following step
Suddenly:
S1, a pair of complementary targeting rabbit HB second extrons of gene of design sgRNA, with pSpCas9 (BB) -2A-Puro
(PX459) V2.0 plasmids are carrier, construct an eukaryotic expression recombinant plasmid;
S2, after sequencing identification, the eukaryotic expression recombinant plasmid is transfected into RK-13 cells jointly, it is mould using purine
Element carries out positive cell screening, and separation monoclonal cell is cultivated;Effect is knocked out with sequencing identification, you can obtain RK-13 thin
The stable strain of born of the same parents HB gene knockouts.
2. the construction method of the stable strain of RK-13 cells HB gene knockouts according to claim 1, it is characterised in that step
In S1, the sequence of the sgRNA includes the forward primer HB-sgRNA F sequences as shown in SEQ ID NO.1, and such as SEQ ID
Reverse primer HB-sgRNA R sequences shown in NO.2.
3. the construction method of the stable strain of RK-13 cells HB gene knockouts according to claim 1, it is characterised in that step
In S1, the structure specifically includes following steps:
S1-1, using Bbs I restriction enzymes pSpCas9 (BB) -2A-Puro (PX459) V2.0 plasmids are linearized,
And be incubated using alkaline phosphatase, remove plasmid end sequence phosphorylation after digestion;Then agarose gel electrophoresis is purified, and is reclaimed
DNA fragmentation;
S1-2, the single-stranded annealing of two sgRNA oligonucleotides formed into double-strand, and through T4 tyrosine phosphorylations;Annealed product
It is attached, and is converted into Stbl3 competent cells, picking list using T4 DNA ligases with the DNA fragmentation of the recovery
Colonies;
S1-3, it is sequenced as primer with U6 promoters, extracts sequencing correct plasmid.
4. the construction method of the stable strain of RK-13 cells HB gene knockouts according to claim 3, it is characterised in that step
In S1-2, the program of T4 tyrosine phosphorylations is 37 DEG C of 30min, 95 DEG C of 5min, 90 DEG C to 25 DEG C 5 DEG C of declines per minute, 4 DEG C of guarantors
Deposit.
5. a kind of eukaryotic expression recombinant plasmid of targeting knock out RK-13 cells HB genes, it is characterised in that the restructuring eucaryon table
It is the sgRNA by designing a pair of complementary targeting rabbit HB second extrons of gene up to plasmid, with pSpCas9 (BB) -2A-
Puro (PX459) V2.0 plasmids are eukaryotic expression recombinant plasmid obtained by vector construction.
6. eukaryotic expression recombinant plasmid according to claim 5, it is characterised in that the sequence of the sgRNA includes such as SEQ
Forward primer HB-sgRNA F sequences shown in ID NO.1, and the reverse primer HB-sgRNA R sequences as shown in SEQ ID NO.2
Row.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710200878.3A CN106987560B (en) | 2017-03-29 | 2017-03-29 | Construction method of RK-13 cell HBB gene knockout stable strain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710200878.3A CN106987560B (en) | 2017-03-29 | 2017-03-29 | Construction method of RK-13 cell HBB gene knockout stable strain |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106987560A true CN106987560A (en) | 2017-07-28 |
CN106987560B CN106987560B (en) | 2020-12-08 |
Family
ID=59411927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710200878.3A Expired - Fee Related CN106987560B (en) | 2017-03-29 | 2017-03-29 | Construction method of RK-13 cell HBB gene knockout stable strain |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106987560B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108085298A (en) * | 2017-11-30 | 2018-05-29 | 中山珐玛斯医药科技有限公司 | The drug absorption screening system and its construction method of a kind of MDCK-MDR1 |
CN109456995A (en) * | 2018-11-08 | 2019-03-12 | 杜以军 | Gene knockout plasmid, cell line and preparation method and application |
WO2019237396A1 (en) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | Method for targeted knockout of human tnfsf18 gene by applying crispr/cas9 system |
WO2020000456A1 (en) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | Method for targeted knockout of human cnih2 gene by applying crispr/cas9 system |
CN112111528A (en) * | 2019-06-21 | 2020-12-22 | 华东师范大学 | Method for repairing abnormal splicing of intron |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105567692A (en) * | 2016-02-26 | 2016-05-11 | 浙江大学 | sgRNA of specific target gene QKI and application thereof |
-
2017
- 2017-03-29 CN CN201710200878.3A patent/CN106987560B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105567692A (en) * | 2016-02-26 | 2016-05-11 | 浙江大学 | sgRNA of specific target gene QKI and application thereof |
Non-Patent Citations (4)
Title |
---|
HAN ZHANG,ET AL.: "CRISPR-Cas9 technology and its application in haematological disorders", 《BRITISH JOURNAL OF HAEMATOLOGY》 * |
YUANYUAN YANG,ET AL.: "Na¨ıve Induced Pluripotent Stem Cells Generated From b-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9", 《STEM CELLS TRANSLATIONALMEDICINE》 * |
徐云飞,等: "血红蛋白β 亚基对猪流行性腹泻病毒增殖抑制作用的研究", 《中国预防兽医学报》 * |
蔡畅,等: "Cas9-CRISPR敲Hae3基因对斑马鱼血红蛋白生成的影响", 《大连海洋大学学报》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108085298A (en) * | 2017-11-30 | 2018-05-29 | 中山珐玛斯医药科技有限公司 | The drug absorption screening system and its construction method of a kind of MDCK-MDR1 |
WO2019237396A1 (en) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | Method for targeted knockout of human tnfsf18 gene by applying crispr/cas9 system |
WO2020000456A1 (en) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | Method for targeted knockout of human cnih2 gene by applying crispr/cas9 system |
CN109456995A (en) * | 2018-11-08 | 2019-03-12 | 杜以军 | Gene knockout plasmid, cell line and preparation method and application |
CN112111528A (en) * | 2019-06-21 | 2020-12-22 | 华东师范大学 | Method for repairing abnormal splicing of intron |
CN112111528B (en) * | 2019-06-21 | 2024-04-02 | 华东师范大学 | Repair method for abnormal splicing of introns |
Also Published As
Publication number | Publication date |
---|---|
CN106987560B (en) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105518138B (en) | Method for specifically knocking out pig GFRA1 gene by CRISPR-Cas9 and sgRNA for specifically targeting GFRA1 gene | |
CN106987560A (en) | The construction method of the stable strain of the cell HB gene knockouts of RK 13 | |
CN105518135B (en) | Method for specifically knocking out pig CMAH gene by CRISPR-Cas9 and sgRNA for specifically targeting CMAH gene | |
CN105492608B (en) | Method for specifically knocking out pig PDX1 gene by CRISPR-Cas9 and sgRNA for specifically targeting PDX1 gene | |
CN105518137B (en) | Method for specifically knocking out pig SALL1 gene by CRISPR-Cas9 and sgRNA for specifically targeting SALL1 gene | |
CN107502608B (en) | Construction method and application of sgRNA and ALDH2 gene-deleted cell strain for knocking out human ALDH2 gene | |
Hao et al. | Fast gene disruption in Trichoderma reesei using in vitro assembled Cas9/gRNA complex | |
WO2016197357A1 (en) | Method for specific knockout of swine sla-3 gene using crispr-cas9 specificity, and sgrna used for specifically targeting sla-3 gene | |
WO2016197356A1 (en) | Method for knockout of swine sla-2 gene using crispr-cas9 specificity, and sgrna used for specifically targeting sla-2 gene | |
CN107418974A (en) | It is a kind of to sort the quick method for obtaining CRISPR/Cas9 gene knockout stable cell lines using monoclonal cell | |
WO2016197361A1 (en) | Method for specific knockout of swine ggta1 gene using crispr-cas9 specificity, and sgrna used for specifically targeting ggta1 gene | |
WO2017190664A1 (en) | Use of chemosynthetic crrna and modified crrna in crispr/cpf1 gene editing systems | |
WO2016187904A1 (en) | Method for pig cmah gene specific knockout by means of crispr-cas9 and sgrna for specially targeting cmah gene | |
WO2016197358A1 (en) | Method for specific knockout of swine fgl-2 gene using crispr-cas9 specificity, and sgrna used for specifically targeting fgl-2 gene | |
CN110358767B (en) | Zymomonas mobilis genome editing method based on CRISPR-Cas12a system and application thereof | |
CN105593367A (en) | CRISPR-Cas9 specificity pig SLA-1 gene knockout method and sgRNA used for specific targeting SLA-1 gene | |
CN104109687A (en) | Construction and application of Zymomonas mobilis CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-association proteins)9 system | |
CN105518140A (en) | Method for pig vWF gene specific knockout through CRISPR-Cas9 and sgRNA for specially targeting vWF gene | |
CN103668472A (en) | Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system | |
CN113215193B (en) | Method for improving activity of gene knockout and base editing system by small molecule compound and application method thereof | |
CN110467679A (en) | A kind of fusion protein, base edit tool and method and its application | |
CN112430586B (en) | VI-B type CRISPR/Cas13 gene editing system and application thereof | |
US20210198670A1 (en) | Method for knocking out n-myristoyltransferase (nmt) gene from eimeria tenella | |
CN116949011A (en) | Isolated Cas13 protein, gene editing system based on same and use thereof | |
CN108893486A (en) | A kind of carrier can be used for filamentous fungi gene knockout and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201208 |